We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Eight Hercules Portfolio Companies Have Completed or Announced an IPO or M&A Liquidity Event Year-to-Date Hercules Congratulates Each Portfolio Company on Their Recent Liquidity...
Closed New Debt and Equity Commitments to Date for Q2 2016 of $203.9 million Eight (8) new commitments to venture growth stage innovative technology, life sciences and sustainable...
Aggregate Proceeds of Notes Increased to $69.0 Million Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”) today announced that in connection with the recent public offering...
Proceeds from offering provide new liquidity to support continued execution of its portfolio and earnings growth strategy Combined 6.25% Notes due 2024 offerings, BBB- rating by...
Hercules Capital, Inc. (NYSE:HTGC) (“Hercules” or the “Company”) announced the pricing of an underwritten public offering of an additional $60.0 million in aggregate principal amount of its...
Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital Growth Capital Allows Alimera to Fulfill Its Milestone Obligation Triggered by FDA Approval of ILUVIEN® PR...
ChromaDex Secures $5.0 Million in Growth Capital Financing from Hercules PR Newswire IRVINE, Calif., Sept. 30, 2014 IRVINE, Calif., Sept. 30, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC...
Celsion Corporation Announces Strategic Loan Facility Up to $20 million in Non-Dilutive Financing Substantially Strengthens Balance Sheet and Provides Additional Funding to Broaden Company's...
InspireMD Secures Financing to Accelerate Advancements in Product Development and Adopts a One Year Stockholder Rights Plan Funding for expansion of clinical trial and product development...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions